ATE332695T1 - Pyrimidin-derivate als selektive inhibitoren von cox-2 - Google Patents

Pyrimidin-derivate als selektive inhibitoren von cox-2

Info

Publication number
ATE332695T1
ATE332695T1 AT02727750T AT02727750T ATE332695T1 AT E332695 T1 ATE332695 T1 AT E332695T1 AT 02727750 T AT02727750 T AT 02727750T AT 02727750 T AT02727750 T AT 02727750T AT E332695 T1 ATE332695 T1 AT E332695T1
Authority
AT
Austria
Prior art keywords
sub
sup
alkyl
group
cox
Prior art date
Application number
AT02727750T
Other languages
English (en)
Inventor
Richard Green
Charles David Hartley
Alan Naylor
Jeremy John Payne
Neil Anthony Pegg
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE332695T1 publication Critical patent/ATE332695T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02727750T 2001-05-25 2002-05-23 Pyrimidin-derivate als selektive inhibitoren von cox-2 ATE332695T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0112810.7A GB0112810D0 (en) 2001-05-25 2001-05-25 Pyrimidine derivatives

Publications (1)

Publication Number Publication Date
ATE332695T1 true ATE332695T1 (de) 2006-08-15

Family

ID=9915330

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02727750T ATE332695T1 (de) 2001-05-25 2002-05-23 Pyrimidin-derivate als selektive inhibitoren von cox-2

Country Status (8)

Country Link
US (2) US7074802B2 (de)
EP (1) EP1392311B1 (de)
JP (1) JP2004534776A (de)
AT (1) ATE332695T1 (de)
DE (1) DE60213087T2 (de)
ES (1) ES2266495T3 (de)
GB (1) GB0112810D0 (de)
WO (1) WO2002096427A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
GB0112803D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112802D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112810D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0119477D0 (en) 2001-08-09 2001-10-03 Glaxo Group Ltd Pyrimidine derivatives
DE60305053T2 (de) 2002-08-19 2006-08-31 Glaxo Group Ltd., Greenford Pyrimidinderivate als selektive cox-2-inhibitoren
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
CA2634940A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
US20090017140A1 (en) * 2007-07-09 2009-01-15 Peter Koepke Maytenus abenfolia extract and methods of extracting and using such extract
US20090035395A1 (en) * 2007-08-01 2009-02-05 Peter Koepke Spondias mombin l. extract and methods of extracting and using such extract
US7879369B2 (en) * 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3149109A (en) * 1962-02-20 1964-09-15 Searle & Co Certain 4-trifluoromethyl-2-(oxy/thio) pyrimidines
GB1121922A (en) * 1966-06-17 1968-07-31 Ici Ltd Pyrimidine derivatives
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CA2277954A1 (en) * 1993-11-30 1995-06-08 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
RU2128996C1 (ru) 1994-09-09 1999-04-20 Ниппон Синяку Ко., Лтд. Гетероциклическое производное и лекарственное средство
US5596008A (en) 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US6342510B1 (en) 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
US6020343A (en) * 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
JPH09241161A (ja) 1996-03-08 1997-09-16 Nippon Shinyaku Co Ltd 医 薬
JPH09266197A (ja) * 1996-03-28 1997-10-07 Mitsubishi Electric Corp 半導体装置およびその製造方法
SI0912518T1 (en) 1996-07-18 2003-12-31 Merck Frosst Canada & Co. Substituted pyridines as selective cyclooxygenase-2 inhibitors
ATE271385T1 (de) 1996-10-15 2004-08-15 Searle Llc Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
JP2002514195A (ja) * 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
EP0994860A1 (de) 1997-07-03 2000-04-26 Du Pont Pharmaceuticals Company Aryl- und arylamino-substituierte heteroringen als corticotropin freisetzende hormon antagonisten
ATE281458T1 (de) * 1997-09-05 2004-11-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
DE19909541A1 (de) 1998-03-06 1999-10-14 American Cyanamid Co Herbizide 2-Aryloxy- bzw. 2-Arylthio-6-arylpyrimidine
US6306866B1 (en) * 1998-03-06 2001-10-23 American Cyanamid Company Use of aryl-substituted pyrimidines as insecticidal and acaricidal agents
US6313072B1 (en) * 1999-02-18 2001-11-06 American Cyanamid Company Herbicidal 2-aryloxy-or 2-arylthio-6-arylpyrimidines
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
GB9930358D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
GB0002336D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
GB0002312D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US6498466B1 (en) * 2000-05-23 2002-12-24 Linear Technology Corp. Cancellation of slope compensation effect on current limit
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
US6756498B2 (en) * 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
GB0112802D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112810D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112803D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
US6861249B1 (en) * 2002-04-09 2005-03-01 David Kent Microbial spray for animal waste

Also Published As

Publication number Publication date
JP2004534776A (ja) 2004-11-18
EP1392311A1 (de) 2004-03-03
DE60213087D1 (de) 2006-08-24
US7074802B2 (en) 2006-07-11
GB0112810D0 (en) 2001-07-18
WO2002096427A1 (en) 2002-12-05
US20050192306A1 (en) 2005-09-01
EP1392311B1 (de) 2006-07-12
US20050032823A1 (en) 2005-02-10
ES2266495T3 (es) 2007-03-01
DE60213087T2 (de) 2006-12-07

Similar Documents

Publication Publication Date Title
WO2003106428A8 (fr) Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
AR021055A1 (es) Derivados de pirazolopiridina
ATE377004T1 (de) Proteinkinaseinhibitoren
HRP20080226T3 (en) Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
ATE457025T1 (de) Kinaseinhibitoren
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
ATE316962T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
DE60213087D1 (de) Pyrimidin-derivate als selektive inhibitoren von cox-2
DE60121461D1 (de) Kondensierte pyridoindolderivate
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
FI964463A0 (fi) Bisykliset amidiinijohdannaiset typpioksidinsyntetaasin inhibiittoreina
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
WO2003068744A1 (en) Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
MY129304A (en) Carbamate compounds for use in preventing or treating bipolar disorder
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
NO995289D0 (no) Benzimidazol-derivater
DE60110124D1 (de) Kondensierte pyrazindionderivate als pde inhibitoren
DK1441726T3 (da) Derivater af phenoxy-N' -4-(isothiazolidin-1,1-dioxid-2-yl)phenyl]-valerianesyreamid og andre forbindelser som inhibitorer af koagulationsfaktoren Xa til behandling af thromboemboliske lidelser og tumorer
WO2002096886A8 (en) Pyrimidine derivatives
HRP20040900B1 (en) Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor x<sub>a</sub>
NO20023381L (no) Indolderivater som MCP-1-reseptoragonister
ATE313260T1 (de) Fungizide mischungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties